Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose determination study of NS-580 in endometriosis (late phase II)
jRCT2031210685Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of friluglanstat in endometriosis (4 arms), sponsored by Nippon Shinyaku. Primary endpoint: pelvic pain. Started Apr 2022; status: completed.
02
Drugs
friluglanstat
03
Conditions
endometriosis
Beyond the preview
Go deeper on jRCT2031210685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210685.